Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Regulatory Replace and Interim Section 1/2 Knowledge Replace for LX2006 for the Therapy of Friedreich Ataxia Cardiomyopathy Name Transcript
Firm Contributors
Louis Tamayo – CFO & Principal Accounting Officer
R. Townsend – CEO & Director
Sandi Tai – Chief Growth Officer
Eric Adler – Chief Medical Officer & Head of Analysis
Convention Name Contributors
Tessa Romero – JPMorgan Chase & Co, Analysis Division
Brian Skorney – Robert W. Baird & Co. Included, Analysis Division
Lili Nsongo – Leerink Companions LLC, Analysis Division
Leland Gershell – Oppenheimer & Co. Inc., Analysis Division
Mitchell Kapoor – H.C. Wainwright & Co, LLC, Analysis Division
Presentation
Operator
Good morning, and welcome to the Lexeo Therapeutics webcast presentation on LX2006 for the therapy of Friedreich’s ataxia cardiomyopathy. As a reminder, this name is being recorded right this moment, October 7, 2025.
I’d now like to show the convention over to Louis Tamayo, Chief Monetary Officer of Lexeo Therapeutics. Louis, please go forward.
Louis Tamayo
CFO & Principal Accounting Officer
Earlier right this moment, we launched the regulatory replace on our discussions up to now with the FDA relating to a possible accelerated approval pathway for LX2006 for the therapy of Friedreich’s ataxia cardiomyopathy alongside new interim medical knowledge from 2 ongoing Section I/II medical research. The press launch outlining these updates is accessible on our web site lexeotx.com, and an 8-Okay was filed with the SEC this morning.
Becoming a member of us on right this moment’s name might be Nolan Townsend, Chief Govt Officer; and Dr. Sandi See Tai, Chief Growth Officer of Lexeo Therapeutics; Dr. Eric Adler, Chief Medical Officer and Head of Analysis; and Dr. Manny Otero, Chief Technical Officer, will even be accessible for Q&A following the decision.
Earlier than we start, I want to remind you that this name will comprise forward-looking statements relating to Lexeo’s future expectations, plans and prospects which represent forward-looking statements
